Filing Overview
Pliant Therapeutics, Inc. filed a Form 8-K reporting an event dated February 4, 2024. The filing concerns interim clinical data from the 320 mg dose group in the Phase 2a INTEGRIS-PSC trial of bexotegrast for patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis.
Clinical and Financial Highlights
- The multinational, randomized, double-blind, placebo-controlled trial reported 12-week interim data for the 320 mg cohort.
- The 320 mg group met its primary and secondary endpoints, demonstrating tolerability over 12 weeks and dose-related increases in plasma bexotegrast concentrations.
- The filing states there was no dose relationship for adverse events.
- Exploratory efficacy measures showed reductions in Enhanced Liver Fibrosis scores and PRO-C3 levels relative to placebo at Week 12.
- Alkaline phosphatase levels were stabilized in bexotegrast-treated patients, compared with an increase in the placebo group.
- MRI results continued to indicate improved hepatocyte function and bile flow relative to placebo.
- The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other financial metrics.
Changes, Outlook, and Risks
The filing reports positive 12-week interim safety and exploratory efficacy findings for the 320 mg dose, consistent with results from lower doses previously tested. It does not provide financial guidance, development timelines, regulatory approvals, or commercialization forecasts.
The data are interim and include exploratory efficacy endpoints. The filing does not state whether the results are statistically significant or provide detailed patient counts, numerical effect sizes, confidence intervals, or complete adverse-event tables. Clinical development, regulatory, efficacy, safety, and trial-continuation risks remain material.
Important Facts to Verify
- Patient enrollment and evaluable sample size for the 320 mg cohort.
- Numerical changes in ELF, PRO-C3, ALP, and MRI measures versus placebo.
- Detailed adverse-event rates, treatment discontinuations, and serious adverse events.
- Statistical significance and durability of the interim findings.
- Future trial design, regulatory plans, and timing for additional INTEGRIS-PSC data.
- Financial runway and funding requirements, which are not addressed in this filing.
Exhibit
Exhibit 99.1 is the February 4, 2024 press release containing the reported clinical data.